Health Trials

About this trial

Studies have shown that combination therapy of TACE with Lenvatinib could achieve better survival outcomes than TACE alone for hepatocellular carcinoma (HCC) at BCLC B stage. However, whether patients could benefit from the ablation for intermediate recurrent HCC (RHCC) is still need high quality clinical evidence. This study is to evaluate the efficacy of ablation combined with TACE and Lenvatinib for the intermediate-stage RHCC.

Eligibility criteria

Qualifiers

18-75 years;

RHCC diagnosed by imaging;

intermediate-stage RHCC (two to three lesions which at least one was >3 cm in size or more than three tumors);

the tumor number was no more than six, and the maximum tumor diameter was ≤5 cm;

Disqualifiers

under 18 years or over 75 years of age;

primary intermediate-stage HCC;

RHCC with more than six tumors, or single RHCC

Trial design

Treatments tested in this trial

  • TACE
  • Ablation
  • Lenvatinb

Treatment groups

116 Participants
are divided into 2 treatment groups

Locations

1
Chinese PLA General hospital100853, BeijingNone Selected, China

Sponsors and collaborators

Sun Yat-sen University

Lead sponsor

Chinese PLA General Hospital

Collaborator

Source ClinicalTrials.gov